Hackensack University Medical Center | |
30 Prospect Ave, Hackensack, New Jersey 07601 | |
(551) 996-2000 | |
Name | Hackensack University Medical Center |
---|---|
Type | Acute Care Hospital |
Location | 30 Prospect Ave, Hackensack, New Jersey |
Ownership | Voluntary non-profit - Private |
Emergency Services | Yes |
Medicare ID (CCN) | 310001 |
NPI Number | 1184649345 |
Organization Name | HACKENSACK UNIVERSITY MEDICAL CENTER |
Address | 30 Prospect Ave, Hackensack, NJ 07601 |
Hospital Type | General Acute Care Hospital - Children |
Phone Number | 201-996-2000 |
News Archive
Galectin-3 sounds like a planet out of "Star Trek," but it can be much more ominous. Recently, distinguished integrative physician Isaac Eliaz, M.D., presented breakthrough research demonstrating that the protein Galectin-3 is an active biomarker for numerous life-threatening diseases. Even more importantly, Dr. Eliaz showed how Modified Citrus Pectin (MCP) binds and blocks Galectin-3 throughout the body.
New research from the UVA Cancer Center could rescue once-promising immunotherapies for treating solid cancer tumors, such as ovarian, colon and triple-negative breast cancer, that ultimately failed in human clinical trials.
Delphi Genetics SA ("Delphi") has organised a ceremony marking the placing of the first stone of its new building on the Aéropole de Charleroi.
NephroGenex, Inc., a privately held drug development company focusing on kidney disease, today announced the completion of patient enrollment in its Phase 2b clinical trial (PYR-210) studying the safety and efficacy of its lead drug candidate Pyridorin (pyridoxamine dihydrochloride) in type 2 diabetic patients with overt diabetic nephropathy. Three hundred and seventeen (317) patients have been randomized.
› Verified 9 days ago
NPI Number | 1457456279 |
Organization Name | HMH HOSPITALS CORPORATION |
Doing Business As | HACKENSACK UNIVERSITY MEDICAL CENTER |
Address | 30 Prospect Ave, Hackensack, NJ 07601 |
Hospital Type | General Acute Care Hospital |
Phone Number | 201-996-5611 |
News Archive
Galectin-3 sounds like a planet out of "Star Trek," but it can be much more ominous. Recently, distinguished integrative physician Isaac Eliaz, M.D., presented breakthrough research demonstrating that the protein Galectin-3 is an active biomarker for numerous life-threatening diseases. Even more importantly, Dr. Eliaz showed how Modified Citrus Pectin (MCP) binds and blocks Galectin-3 throughout the body.
New research from the UVA Cancer Center could rescue once-promising immunotherapies for treating solid cancer tumors, such as ovarian, colon and triple-negative breast cancer, that ultimately failed in human clinical trials.
Delphi Genetics SA ("Delphi") has organised a ceremony marking the placing of the first stone of its new building on the Aéropole de Charleroi.
NephroGenex, Inc., a privately held drug development company focusing on kidney disease, today announced the completion of patient enrollment in its Phase 2b clinical trial (PYR-210) studying the safety and efficacy of its lead drug candidate Pyridorin (pyridoxamine dihydrochloride) in type 2 diabetic patients with overt diabetic nephropathy. Three hundred and seventeen (317) patients have been randomized.
› Verified 9 days ago
NPI Number | 1467657452 |
Organization Name | HACKENSACK UNIVERSITY MEDICAL CENTER |
Address | 30 Prospect Ave, Hackensack, NJ 07601 |
Hospital Type | General Acute Care Hospital |
Phone Number | 201-996-2450 |
News Archive
Galectin-3 sounds like a planet out of "Star Trek," but it can be much more ominous. Recently, distinguished integrative physician Isaac Eliaz, M.D., presented breakthrough research demonstrating that the protein Galectin-3 is an active biomarker for numerous life-threatening diseases. Even more importantly, Dr. Eliaz showed how Modified Citrus Pectin (MCP) binds and blocks Galectin-3 throughout the body.
New research from the UVA Cancer Center could rescue once-promising immunotherapies for treating solid cancer tumors, such as ovarian, colon and triple-negative breast cancer, that ultimately failed in human clinical trials.
Delphi Genetics SA ("Delphi") has organised a ceremony marking the placing of the first stone of its new building on the Aéropole de Charleroi.
NephroGenex, Inc., a privately held drug development company focusing on kidney disease, today announced the completion of patient enrollment in its Phase 2b clinical trial (PYR-210) studying the safety and efficacy of its lead drug candidate Pyridorin (pyridoxamine dihydrochloride) in type 2 diabetic patients with overt diabetic nephropathy. Three hundred and seventeen (317) patients have been randomized.
› Verified 9 days ago
NPI Number | 1609862036 |
Organization Name | HACKENSACK UNIVERSITY MEDICAL CENTER |
Address | 30 Prospect Ave, Hackensack, NJ 07601 |
Hospital Type | General Acute Care Hospital |
Phone Number | 201-996-2210 |
News Archive
Galectin-3 sounds like a planet out of "Star Trek," but it can be much more ominous. Recently, distinguished integrative physician Isaac Eliaz, M.D., presented breakthrough research demonstrating that the protein Galectin-3 is an active biomarker for numerous life-threatening diseases. Even more importantly, Dr. Eliaz showed how Modified Citrus Pectin (MCP) binds and blocks Galectin-3 throughout the body.
New research from the UVA Cancer Center could rescue once-promising immunotherapies for treating solid cancer tumors, such as ovarian, colon and triple-negative breast cancer, that ultimately failed in human clinical trials.
Delphi Genetics SA ("Delphi") has organised a ceremony marking the placing of the first stone of its new building on the Aéropole de Charleroi.
NephroGenex, Inc., a privately held drug development company focusing on kidney disease, today announced the completion of patient enrollment in its Phase 2b clinical trial (PYR-210) studying the safety and efficacy of its lead drug candidate Pyridorin (pyridoxamine dihydrochloride) in type 2 diabetic patients with overt diabetic nephropathy. Three hundred and seventeen (317) patients have been randomized.
› Verified 9 days ago
Able to receive lab results electronically | Yes |
Able to track patients' lab results, tests, and referrals electronically between visits | Yes |
News Archive
Galectin-3 sounds like a planet out of "Star Trek," but it can be much more ominous. Recently, distinguished integrative physician Isaac Eliaz, M.D., presented breakthrough research demonstrating that the protein Galectin-3 is an active biomarker for numerous life-threatening diseases. Even more importantly, Dr. Eliaz showed how Modified Citrus Pectin (MCP) binds and blocks Galectin-3 throughout the body.
New research from the UVA Cancer Center could rescue once-promising immunotherapies for treating solid cancer tumors, such as ovarian, colon and triple-negative breast cancer, that ultimately failed in human clinical trials.
Delphi Genetics SA ("Delphi") has organised a ceremony marking the placing of the first stone of its new building on the Aéropole de Charleroi.
NephroGenex, Inc., a privately held drug development company focusing on kidney disease, today announced the completion of patient enrollment in its Phase 2b clinical trial (PYR-210) studying the safety and efficacy of its lead drug candidate Pyridorin (pyridoxamine dihydrochloride) in type 2 diabetic patients with overt diabetic nephropathy. Three hundred and seventeen (317) patients have been randomized.
› Verified 9 days ago
Hackensack University Medical Center Acute Care Hospital Location: 30 Prospect Ave, Hackensack, New Jersey 07601 Phone: (551) 996-2000 |